Streetbeat News

Regulatory

SPY

VGK

NATO allies have committed to providing billions of euros in additional capabilities to Ukraine in 2024, according to a statement cited by Reuters.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 5:11 pm

SVRE

SaverOne 2014 has received a decision to grant a European patent for its 'SYSTEM AND METHODS TO FACILITATE SAFE DRIVING'. The patent approval is a significant milestone for the company, potentially strengthening its intellectual property portfolio and market position in Europe.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 5:07 pm

BTCUSD

Prediction market traders on Polymarket believe there is an 88% chance of a spot Bitcoin ETF being approved by the SEC by January 15, with a 77% chance of approval on Wednesday. The market has seen over $8.5 million in volume, with one trader betting $1.4 million on the approval. The SEC's account was hacked on Tuesday, causing fluctuations in the approval odds. Bloomberg ETF analyst Eric Balchunas expects approval on Wednesday, with preparations underway at Bloomberg.

Portfolio Pulse from Khyathi Dalal

January 10, 2024 | 4:57 pm

GHM

Brandes Investment Partners has disclosed an 11% stake in Graham Corporation through a 13G filing with the SEC.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 4:44 pm

SPR

Spirit AeroSystems Holdings, Inc. (SPR) has announced its direct support for the National Transportation Safety Board's (NTSB) investigation. The nature of the investigation or its implications for Spirit AeroSystems were not detailed in the announcement.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 4:13 pm

BTCUSD

The SEC's hacked Twitter account falsely indicated approval of a Bitcoin ETF, causing Bitcoin's price to fluctuate and over $200 million to be liquidated. Despite concerns, analysts believe the Wednesday deadline for ETF approval will not be affected. Nate Geraci of ETFStore and Ophelia B Snyder of 21Shares both expect the process to continue as scheduled. An SEC spokesperson confirmed that any approvals would be reflected in the EDGAR database. A poll by Shardi B Trading showed market confidence shaken, but Reuters sources and eTORO analyst Josh Gilbert remain optimistic about the approval and potential for a 'sell the news' event.

Portfolio Pulse from Khyathi Dalal

January 10, 2024 | 4:13 pm

BTCUSD

ETHUSD

Bitcoin's price fell below $45,000 after a false start on ETF approval due to a hacked SEC tweet. Analysts from QCP Capital and K33 Research suggest that an actual ETF approval may not significantly impact Bitcoin's price as it might be already priced in. They also note potential changes in market dynamics, such as reduced volatility and influence of crypto whales, and impacts on the futures market. Ethereum's standing in relation to Bitcoin is also discussed.

Portfolio Pulse from Murtuza Merchant

January 10, 2024 | 3:31 pm

CMND

Clearmind Medicine Inc (NASDAQ:CMND) stock soared after announcing the completion of a Type A meeting with the FDA regarding its clinical trial for CMND-100, a compound for treating Alcohol Use Disorder with psychedelic-based therapy. The active ingredient, MEAI, is reported to reduce alcohol consumption desires while providing a euphoric experience. The company aims to resubmit its IND for CMND-100 and bring new treatment options for AUD.

Portfolio Pulse from Adam Eckert

January 10, 2024 | 2:57 pm

QQQ

SPY

TLT

The upcoming December inflation report is critical for the Federal Reserve's rate decisions in Q1 2024. Economists expect a slight increase in annual CPI to 3.2% from November's 3.1%, with core CPI predicted to decline to 3.8% from 4%. Goldman Sachs projects slightly higher rates, while Bank of America aligns with consensus and suggests a potential rate cut in March if inflation is softer than expected. November's CPI report aligned with forecasts, leading to gains in SPY and QQQ, and a rise in TLT as Treasury yields fell.

Portfolio Pulse from Piero Cingari

January 10, 2024 | 2:45 pm

CMND

Clearmind Medicine's stock price has increased following the announcement of a completed Type A meeting with the U.S. Food and Drug Administration.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 2:43 pm